Skip to main content

Table 4 Measures of CMD and cardiovascular risk factors

From: Coronary microvascular function and myocardial fibrosis in women with angina pectoris and no obstructive coronary artery disease: the iPOWER study

 

Coronary Flow Velocity Reserve

Myocardial Blood Flow Reserve

<2

2-2.5

>2.5

p-value*

<2

2-2.5

>2.5

p-value*

(n = 23)

(n = 16)

(n = 25)

 

(n = 6)

(n = 13)

(n = 35)

 

MBFR/CFVR, median (IQR)

2.2 (2.0;2.7)

2.7 (2.4;2.8)

2.9 (2.5;3.2)

0.01**

2.4 (1.9;2.7)

2.0 (1.7;2.3)

2.6 (2.2;2.9)

0.01**

T1 native (ms), mean (SD)

1046 (123)

1005 (123)

1014 (51)

0.61**

985 (34)

1053 (159)

1013 (55)

0.64**

ECV (%), mean (SD)

34.5 (4.5)

32.6 (2.2)

33.7 (2.9)

0.27**

31.2 (2.7)

34.2 (3.9)

33.6 (2.6)

0.13**

Age (years), mean (SD)

64.0 (10.3)

61.2 (6.4)

61.8 (7.49

0.52

60.2 (7.5)

63.1 (8.6)

61.9 (7.2)

0.74

BMI (kg/m2), median (IQR)

24 (22;27)

23 (21;28)

25 (23;29)

0.42

26 (24;29)

23 (22;24)

25 (22;29)

0.46

Hypertension, n (%)

20 (89)

10 (63)

8 (32)

0.002

5 (83)

10 (77)

14 (40)

0.03

Smoking (current), n (%)

6 (26)

4 (25)

5 (20)

0.87

3 (50)

4 (31)

5 (14)

0.13

Ever smoked, n (%)

14 (61)

14 (88)

11 (44)

0.04

5 (83)

10 (77)

19 (54)

0.22

Atherosclerosis on CAG, n (%)

12 (52)

10 (63)

7 (28)

0.08

5 (83)

5 (39)

14 (40)

0.20

Non-HDL cholesterol, mean (SD)

3.2 (1.0)

3.0 (0.9)

3.5 (1.0)

0.36

3.0 (1.2)

3.5 (0.8)

3.2 (1.1)

0.59

Systolic BP (mmHg), mean (SD)

142 (24)

156 (22)

149 (28)

0.28

151 (18)

141 (30)

148 (26)

0.68

Resting HR (bpm), mean (SD)

68 (10)

68 (12)

60 (9)

0.02

68 (15)

70 (9)

61 (104)

0.05

Ejection fraction (%), mean (SD)

58.6 (6.7)

61.7 (4.2)

59.4 (6.0)

0.30

57.6 (10.0)

58.6 (6.1)

60.6 (4.9)

0.39

LV mass index (g/m2), mean (SD)

45.8 (6.0)

49.7 (8.2)

50.1 (8.2)

0.12

49.4 (2.3)

47.3 (9.8)

49.9 (7.7)

0.61

LV hypertrophy, n (%)

0 (0)

2 (15)

3 (12)

0.96

0 (0)

1 (8)

4 (11)

0.90

ESC HeartScore (% risk)a, mean (SD)

1.3 (1.0)

1.4 (1.2)

1.3 (1.5)

0.91

1.2 (0.8)

1.6 (1.4)

1.2 (1.2)

0.59

Framingham risk scoreb, mean (SD)

0.09 (0.04)

0.1 (0.06)

0.09 (0.06)

0.61

0.1 (0.1)

0.08 (0.03)

0.09 (0.05)

0.67

Beta blockers, n (%)

7 (30)

6 (38)

10 (40)

0.78

1 (17)

5 (38)

13 (37)

0.62

Acetylsalicylic acid, n (%)

14 (61)

7 (44)

14 (56)

0.57

6 (100)

6 (46)

17 (49)

0.10

Statin, n (%)

15 (65)

9 (56)

11 (44)

0.34

6 (100)

5 (38)

17 (48.6)

0.82

Calcium antagonists, n (%)

8 (35)

3 (19)

6 (25)

0.53

3 (50)

3 (23)

7 (21)

0.34

ACE inhibitor, n (%)

2 (9)

4 (25)

2 (8)

0.26

1 (17)

2 (15)

4 (12)

0.92

Ang. Rec. Blockers, n (%)

7 (30)

2 (13)

2 (8)

0.14

0 (0)

2 (15)

4 (12)

0.95

  1. *Difference between groups was tested by trend test: multiple regression for continuous variables & logistic regression for categorical outcome variables. Log transformed values for the outcome variable was used for the skewed variables. ** P-value obtained from Pearson’s correlation coefficient. aEstimates absolute risk (%) for cardiovascular death within 10 years. bEstimates risk for coronary heart disease over a period of 10 years (1 = 100 % risk)
  2. ECV extracellular volume fraction, CFVR coronary flow velocity reserve, MBFR myocardial blood flow reserve, IQR interquartile range, SD standard deviation, BMI body mass index, CAG coronary angiography, non-HDL Non-high-density-lipoprotein cholesterol, HR heart rate, BP blood pressure, LV left ventricle, ESC European Society of Cardiology, ACE Angiotensin converting enzyme, Ang.Rec. angiotensin receptor
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us